ALLR — Allarity Therapeutics Share News
0.000.00%
Last trade - 00:00- $13.77m
- $19.07m
- $0.32m
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic
Allarity Therapeutics Q1 net loss per share narrows
Brief: Allarity Therapeutics Announces That The Stenoparib Drp® Test Has Received A Notice Of Allowance From The Us Patent And Trademark Office
Brief: Allarity Therapeutics Reports Full Year 2025 Financial Results And Corporate Progress
Brief: Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization
Brief: Allarity Therapeutics And US Veteran’S Administration Open Enrollment For Mid-Stage Trial Of Stenoparib With Temozolomide In Relapsed Small Cell Lung Cancer
Brief: Allarity Therapeutics Inc - To Offer Up To $50 Million In Securities
Allarity Therapeutics's Q3 net loss narrows
U.S. RESEARCH ROUNDUP- Carmax, Mirion Technologies, Valmont Industries
U.S. STOCKS ON THE MOVE-Advanced Micro Devices, ImmunityBio, Trump Media
U.S. STOCKS ON THE MOVE-Trump Media, Gold miners, Cracker Barrel
Allarity more than doubles on US FDA's 'fast track' tag for ovarian cancer therapy
U.S. STOCKS ON THE MOVE-Constellation Brands, Bank of Montreal, Advanced Micro Devices
Allarity Therapeutics jumps on US FDA's 'fast track' tag for ovarian cancer therapy
Brief: Allarity Therapeutics Granted FDA Fast Track Designation For Stenoparib For The Treatment Of Advanced Ovarian Cancer
U.S. RESEARCH ROUNDUP-Cognizant, Lam Research, Sarepta Therapeutics